ストックスクリーナーアプリを入手
7.928
1.17%
-0.052
前日終値:
$7.98
開ける：
$8.08
24時間の取引高:
40,085
Relative Volume:
0.06
時価総額：
$921.95M
収益：
-
当期純損益:
$-174.61M
株価収益率:
-3.7573
EPS:
-2.11
ネットキャッシュフロー:
$-165.54M
1週間 パフォーマンス:
-9.87%
1か月 パフォーマンス:
-3.00%
6か月 パフォーマンス:
-11.88%
1年 パフォーマンス:
+3.91%
1日の値動き範囲:
$7.80
$8.0992
1週間の範囲:
$7.675
$8.85
52週間の値動き範囲:
$7.00
$16.63
89 Bio Inc Stock (ETNB) Company Profile
ETNB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ETNB | 7.945 | 921.95M | 0 | -174.61M | -165.54M | -2.11 |
| VRTX | 447.17 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.51 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.70 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 250.25 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-05-12 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2021-12-20 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-26 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-07-29 | 再開されました | BTIG Research | Buy |
| 2021-05-25 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2021-04-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-10-19 | 開始されました | Raymond James | Strong Buy |
| 2020-09-25 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-07-23 | 開始されました | BTIG Research | Buy |
| 2020-07-07 | 開始されました | Chardan Capital Markets | Buy |
| 2019-12-09 | 開始されました | BofA/Merrill | Neutral |
| 2019-12-09 | 開始されました | Oppenheimer | Outperform |
| 2019-12-09 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-12-09 | 開始されました | SVB Leerink | Outperform |
すべてを表示
89 Bio Inc (ETNB) 最新ニュース
89Bio Inc. Reports Q3 2024 Financial Results - TipRanks
RA CAPITAL MANAGEMENT, L.P. Increases Stake in 89bio Inc - GuruFocus.com
89bio Inc.’s $125 Million Common Stock Offering - Global Legal Chronicle
Syncona building Slingshot incubator; Trace launches with $101M - BioCentury
89bio reports potential MASH treatment progress By Investing.com - Investing.com Canada
89bio reports potential MASH treatment progress - Investing.com
89bio's Pegozafermin Shows Promising Results in Advanced MASH Treatment Trial | ETNB Stock News - StockTitan
89bio, Inc. announces public offering and warrant issuance - Investing.com
Janus Henderson Group PLC's Strategic Acquisition in 89bio Inc - GuruFocus.com
FY2024 EPS Estimates for 89bio Lowered by Cantor Fitzgerald - MarketBeat
HC Wainwright Issues Pessimistic Estimate for 89bio Earnings - MarketBeat
89bio announces $100 million public stock offering - Investing.com India
SEC Form 424B5 filed by 89bio Inc. - Quantisnow
89bio drops 2%, prices $125M stock offering - MSN
89bio announces $100 million public stock offering By Investing.com - Investing.com Australia
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
89bio Raises $125M in Upsized Public Offering at $8.50 Per Share | ETNB Stock News - StockTitan
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Inc.
ETNB89bio, Inc. Latest Stock News & Market Updates - StockTitan
89bio announces proposed underwritten public offering of common stock and pre-funded warrants - MSN
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
BioLife Solutions Surges 30% in Q3 Revenue, Slashes Net Loss by 89% | Earnings Report | BLFS Stock News - StockTitan
89bio Launches $100M Public Offering to Advance Pegozafermin Development | ETNB | ETNB Stock News - StockTitan
GLP-1s push into MASH as semaglutide 2.4 mg hits endpoints - BioWorld Online
89bio Inc (ETNB) Quarterly 10-Q Report - Quartzy
89bio, Inc. (NASDAQ:ETNB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
HC Wainwright Reaffirms Buy Rating for 89bio (NASDAQ:ETNB) - MarketBeat
FY2028 Earnings Estimate for 89bio Issued By Leerink Partnrs - MarketBeat
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Raymond James Issues Pessimistic Forecast for 89bio (NASDAQ:ETNB) Stock Price - MarketBeat
89bio Reports Third Quarter 2024 Financial Results and Corporate UpdatesSAN FRANCISCO, November 7, 2024 (GLOBE NEWSWIRE) – On November 7, 2024, 89bio, Inc. (NASDAQ: ETNB), a clinical-stage biopharmaceutical company focusing on innovativ - Defense World
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates - The Manila Times
89bio Inc (ETNB) Has A Gold Mine On Its Hands - Stocks Register
Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Harbor Capital Advisors Inc. Purchases 142,032 Shares of 89bio, Inc. (NASDAQ:ETNB) - MarketBeat
89bio to Participate in the UBS Global Healthcare Conference - The Manila Times
89bio to Present at UBS Global Healthcare Conference: Key Investor Updates Coming | ETNB Stock News - StockTitan
Lyft Inc Cl A (LYFT-Q) QuotePress Release - The Globe and Mail
UBS Group Ag ADR (UBS-N) QuotePress Release - The Globe and Mail
89bio (NASDAQ:ETNB) Shares Gap DownHere's What Happened - MarketBeat
Block Inc (SQ-N) QuotePress Release - The Globe and Mail
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH - Yahoo Finance
89bio's chief technical operations officer sells $226,994 in stock - Investing.com India
89bio's chief technical operations officer sells $226,994 in stock By Investing.com - Investing.com Australia
89bio (NASDAQ:ETNB) Trading 7.3% HigherStill a Buy? - MarketBeat
Coinbase Global Inc Cl A (COIN-Q) QuotePress Release - The Globe and Mail
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
89Bio: Surviving A Competitive SpaceFor Now (NASDAQ:ETNB) - Seeking Alpha
Global Severe Hypertriglyceridemia (SHTG) Treatment Market Set to Reach USD 2675.37 Million by 2033 - PharmiWeb.com
Bank of America Corp (BAC-N) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
89 Bio Inc (ETNB) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):